El Hospital General Universitario de Valencia, también conocido como Hospital general u Hospital provincial, es un centro hospitalario español ubicado en el distrito de L'Olivereta, en la ciudad de Valencia. Fue el antiguo Hospicio de Fray Juan Gilaberto Jofré, fundado en el siglo XV.

During the past decade, Hospital General Universitario de Valencia conducted 225 clinical trials. In the 10-year time frame, 225 clinical trials started and 64 clinical trials were completed, i.e. on average, 28.4% percent of trials that started reached the finish line to date. In the past 5 years, 119 clinical trials started and 42 clinical trials were completed. i.e. 35.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Hospital General Universitario de Valencia" #1 sponsor was "Pfizer" with 15 trials, followed by "Fundación GECP" with 12 trials sponsored, "Gilead Sciences" with 12 trials sponsored, "Spanish Lung Cancer Group" with 12 trials sponsored and "Bayer" with 12 trials sponsored. Other sponsors include 276 different institutions and companies that sponsored additional 160 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Hospital General Universitario de Valencia" #1 collaborator was "Bristol-Myers Squibb" with 9 trials as a collaborator, "Eli Lilly and Company" with 7 trials as a collaborator, "Pfizer" with 7 trials as a collaborator, "Hoffmann-La Roche" with 6 trials as a collaborator and "Merck Sharp & Dohme LLC" with 6 trials as a collaborator. Other collaborators include 170 different institutions and companies that were collaborators in the rest 134 trials.

According to Clinical.Site data, the most researched conditions in "Hospital General Universitario de Valencia" are "Breast Cancer" (11 trials), "Heart Failure" (11 trials), "Lung Cancer" (10 trials), "Carcinoma, Non-Small-Cell Lung" (7 trials) and "Chronic Hepatitis C" (7 trials). Many other conditions were trialed in "Hospital General Universitario de Valencia" in a lesser frequency.

Most popular intervention types in "Hospital General Universitario de Valencia" are "Drug" (250 trials), "Other" (29 trials), "Procedure" (23 trials), "Biological" (19 trials) and "Device" (18 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (66 trials), "Carboplatin" (13 trials), "Paclitaxel" (10 trials), "Pembrolizumab" (8 trials) and "Nivolumab" (7 trials). Other intervention names were less common.

The vast majority of trials in "Hospital General Universitario de Valencia" are 314 trials for "All" genders, 26 trials for "Female" genders and 3 trials for "Male" genders.

Currently, there are 119 active trials in "Hospital General Universitario de Valencia". 1 are not yet recruiting, 73 are recruiting, 44 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 166 completed trials in Hospital General Universitario de Valencia, 1 suspended trials, and 36 terminated clinical trials to date.

Out of the total trials that were conducted in Hospital General Universitario de Valencia, 14 "Phase 1" clinical trials were conducted, 106 "Phase 2" clinical trials and 116 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 29 trials, and there were also 18 trials that are defined as “Not Applicable".